Synthesis, Antibacterial, and Cytotoxicity Evaluation of Oleanolic Acid-4-aminoquinoline Based Hybrid Compounds-Reference-Cited by-同舟云学术

Synthesis, Antibacterial, and Cytotoxicity Evaluation of Oleanolic Acid-4-aminoquinoline Based Hybrid Compounds

Published:2021-08 Issue:2 Volume:16 Page:122-136
ISSN:2772-4344
Container-title:Recent Advances in Anti-Infective Drug Discovery
language:en
Short-container-title:RAAIDD

Author:

Khwaza Vuyolwethu¹,Oyedeji Opeoluwa O.¹,Aderibigbe Blessing A.¹^ORCID,Morifi Eric²,Fonkui Thierry Y.³,Ndinteh Derek T.⁴,Steenkamp Vanessa⁵

Affiliation:

1. Department of Chemistry, University of Fort Hare, Alice Campus, Alice, Eastern Cape,South Africa

2. School of Chemistry, Mass Spectrometry division, University of Witwatersrand, Johannesburg,South Africa

3. Department of Biotechnology and Food Technology, University of Johannesburg, Doornfontein Campus, Johannesburg,South Africa

4. Department of Applied Chemistry, University of Johannesburg, Doornfontein Campus, Johannesburg,South Africa

5. Department of Pharmacology, Faculty of Health Sciences, University of Pretoria, Pretoria,South Africa

Abstract

Aim: To prepare a class of oleanolic-based compounds. Background: Conventional drugs used to treat infectious diseases suffer from limitations such as drug toxicity and drug resistance. The resistance of microbes to antimicrobial agents is a significant challenge in treating microbial infections. Combining two or more drugs with different modes of action to treat microbial infections results in a delay in developing drug resistance by the microbes. However, it is challenging to select the appropriate choice of drugs for combination therapy due to the differences in stability and pharmacokinetic proﬁle of the drugs.Therefore, developing hybrid compounds using the existing drugs is a promising approach to design effective antimicrobial agents. Objectives: To prepare oleanolic-based hybrid compounds followed by characterization, in vitro antibacterial, and cytotoxicity evaluation. Methods:: Oleanolic acid-4-aminoquinoline-based hybrid compounds weresynthesized via esterification and amidation. The compounds werecharacterized using FTIR, NMR, and UHPLC-HRMS. Oleanolic acid was isolated from the flower buds of Syszygium aromaticum (L.) Merr. & L.M.Perry, a specie from Kingdom Plantae, order Mytales in Myrtaceae family. Their antibacterial and cytotoxicity activity was determined against selected strains of bacteria assessed using the microdilution assay and sulforhodamine B assay against selected cancer cell lines. Results: The synthesized hybrid compounds exhibited antibacterial activity against the Gram-positive bacteria Enterococcus faecalis (ATCC13047), Bacillus subtilis (ATCC19659), Staphylococcus aureus as well as Gram-negative bacteria, Klebsiella oxytoca (ATCC8724), Escherischia coli (ATCC25922), and Proteus vulgaris (ATCC6380) with minimum inhibitory concentrations of 1.25 mg/mL compared to oleanolic acid (2.5 mg/mL). Compounds 13 and 14 displayed cytotoxicity in vitro against the cancer cell lines (MCF-7 and DU 145) compared to the oleanolic acid (IC50 ˃ 200 μM). Conclusion: The present study revealed that the modification of C28 of OA enhanced its biological properties.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery

Reference65 articles.

1. Lozano R.; Naghavi M.; Foreman K.; Lim S.; Shibuya K.; Aboyans V.; Abraham J.; Adair T.; Aggarwal R.; Ahn S.Y.; Alvarado M.; Anderson H.R.; Anderson L.M.; Andrews K.G.; Atkinson C.; Baddour L.M.; Barker-Collo S.; Bartels D.H.; Bell M.L.; Benjamin E.J.; Bennett D.; Bhalla K.; Bikbov B.; Bin Abdulhak A.; Birbeck G.; Blyth F.; Bolliger I.; Boufous S.; Bucello C.; Burch M.; Burney P.; Carapetis J.; Chen H.; Chou D.; Chugh S.S.; Coffeng L.E.; Colan S.D.; Colquhoun S.; Colson K.E.; Condon J.; Connor M.D.; Cooper L.T.; Corriere M.; Cortinovis M.; de Vaccaro K.C.; Couser W.; Cowie B.C.; Criqui M.H.; Cross M.; Dabhadkar K.C.; Dahodwala N.; De Leo D.; Degenhardt L.; Delossantos A.; Denenberg J.; Des Jarlais D.C.; Dharmaratne S.D.; Dorsey E.R.; Driscoll T.; Duber H.; Ebel B.; Erwin P.J.; Espindola P.; Ezzati M.; Feigin V.; Flaxman A.D.; Forouzanfar M.H.; Fowkes F.G.; Franklin R.; Fransen M.; Freeman M.K.; Gabriel S.E.; Gakidou E.; Gaspari F.; Gillum R.F.; Gonzalez-Medina D.; Halasa Y.A.; Haring D.; Harrison J.E.; Havmoeller R.; Hay R.J.; Hoen B.; Hotez P.J.; Hoy D.; Jacobsen K.H.; James S.L.; Jasrasaria R.; Jayaraman S.; Johns N.; Karthikeyan G.; Kassebaum N.; Keren A.; Khoo J.P.; Knowlton L.M.; Kobusingye O.; Koranteng A.; Krishnamurthi R.; Lipnick M.; Lipshultz S.E.; Ohno S.L.; Mabweijano J.; MacIntyre M.F.; Mallinger L.; March L.; Marks G.B.; Marks R.; Matsumori A.; Matzopoulos R.; Mayosi B.M.; McAnulty J.H.; McDermott M.M.; McGrath J.; Mensah G.A.; Merriman T.R.; Michaud C.; Miller M.; Miller T.R.; Mock C.; Mocumbi A.O.; Mokdad A.A.; Moran A.; Mulholland K.; Nair M.N.; Naldi L.; Narayan K.M.; Nasseri K.; Norman P.; O’Donnell M.; Omer S.B.; Ortblad K.; Osborne R.; Ozgediz D.; Pahari B.; Pandian J.D.; Rivero A.P.; Padilla R.P.; Perez-Ruiz F.; Perico N.; Phillips D.; Pierce K.; Pope C.A.; Porrini E.; Pourmalek F.; Raju M.; Ranganathan D.; Rehm J.T.; Rein D.B.; Remuzzi G.; Rivara F.P.; Roberts T.; De León F.R.; Rosenfeld L.C.; Rushton L.; Sacco R.L.; Salomon J.A.; Sampson U.; Sanman E.; Schwebel D.C.; Segui-Gomez M.; Shepard D.S.; Singh D.; Singleton J.; Sliwa K.; Smith E.; Steer A.; Taylor J.A.; Thomas B.; Tleyjeh I.M.; Towbin J.A.; Truelsen T.; Undurraga E.A.; Venketasubramanian N.; Vijayakumar L.; Vos T.; Wagner G.R.; Wang M.; Wang W.; Watt K.; Weinstock M.A.; Weintraub R.; Wilkinson J.D.; Woolf A.D.; Wulf S.; Yeh P.H.; Yip P.; Zabetian A.; Zheng Z.J.; Lopez A.D.; Murray C.J.; AlMazroa M.A.; Memish Z.A.; Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012,380(9859),2095-2128

2. Walvekar P.; Gannimani R.; Govender T.; Combination drug therapy via nanocarriers against infectious diseases. Eur J Pharm Sci 2019,127,121-141

3. Taganna J.C.; Quanico J.P.; Perono R.M.G.; Amor E.C.; Rivera W.L.; Tannin-rich fraction from Terminalia catappa inhibits quorum sensing (QS) in Chromobacterium violaceum and the QS-controlled biofilm maturation and LasA staphylolytic activity in Pseudomonas aeruginosa. J Ethnopharmacol 2011,134(3),865-871

4. Morgan D.J.; Okeke I.N.; Laxminarayan R.; Perencevich E.N.; Weisenberg S.; Non-prescription antimicrobial use worldwide: a systematic review. Lancet Infect Dis 2011,11(9),692-701

5. Centers for Disease Control and prevention (CDC). Available on: https://www.cdc.gov/drugresistance/biggest_threats.html.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biological Activities of Novel Oleanolic Acid Derivatives from Bioconversion and Semi-Synthesis;Molecules;2024-06-28

2. Exploring diverse frontiers: Advancements of bioactive 4-aminoquinoline-based molecular hybrids in targeted therapeutics and beyond;European Journal of Medicinal Chemistry;2024-01

3. Synthesis of Ester‐Linked Ursolic Acid‐Based Hybrid Compounds: Potential Antibacterial and Anticancer Agents;Chemistry & Biodiversity;2023-03-28

4. Design, semi-synthesis and molecular docking of new antibacterial and antibiofilm triazole conjugates from hydroxy-triterpene acids and fluoroquinolones;New Journal of Chemistry;2023

5. Recent advances in medicinal chemistry of oleanolic acid derivatives;Phytochemistry;2022-11